Feasibility of CBCT-based proton dose calculation using a histogram-matching algorithm in proton beam therapy

2017 ◽  
Vol 33 ◽  
pp. 68-76 ◽  
Author(s):  
Kazuhiro Arai ◽  
Noriyuki Kadoya ◽  
Takahiro Kato ◽  
Hiromitsu Endo ◽  
Shinya Komori ◽  
...  
2016 ◽  
Vol 43 (6Part46) ◽  
pp. 3886-3886
Author(s):  
K Arai ◽  
N Kadoya ◽  
T Kato ◽  
H Endo ◽  
S Komori ◽  
...  

Author(s):  
Elham Piruzan ◽  
Naser Vosoughi ◽  
Hojjat Mahani

Purpose: Proton Beam Therapy (PBT) is an emerging radiotherapy technique using beams of proton to treat cancer. As the first report addressing the topic, the principal aim is to highlight the present status of PBT research and development in Iran as a developing country. Materials and Methods: To do so, the demand for PBT in Iran and Iran National Ion Therapy Center (IRNitc) was investigated and introduced. Then, Scopus and PubMed were searched for studies that dealt with PBT research in Iran and subsequently 6 major subfields of interest were identified. Furthermore, international collaborations were extracted from the bibliographic data. To combine both research and development sides, a SWOT analysis was performed through collecting viewpoints of 48 radiotherapy experts about PBT, and then strengths, weaknesses, opportunities, and threats of it were examined. Results: Iran contributes to approximately 1% of global PBT sciences. Proton dose calculation using Monte Carlo simulation is the dominant subject of interest for Iranian researchers. Italy is recognized as the major foreign partner in PBT researches. Clinical advantages over conventional radiotherapy modalities are the main strength of PBT development in Iran while the high installation cost remains the most weakness. Finally, 10 general considerations for the launching of a PBT facility in Iran were presented based upon both Iranian experts’ viewpoints and IAEA recommendations. Conclusion: This research reveals that while PBT research and development in Iran are still in their infancy, there are promising trends in both the research and development sides of PBT.


2008 ◽  
Vol 53 (17) ◽  
pp. 4825-4853 ◽  
Author(s):  
Harald Paganetti ◽  
Honggu Jiang ◽  
Katia Parodi ◽  
Roelf Slopsema ◽  
Martijn Engelsman

2020 ◽  
Vol 152 ◽  
pp. S766-S767
Author(s):  
S. Ruangchan ◽  
B. Knäusl ◽  
H. Fuchs ◽  
D. Georg ◽  
M. Clausen

2019 ◽  
Author(s):  
Gustavo Rangel ◽  
Mostafa Shahein ◽  
Thiago Felicio ◽  
Guilhermo Malave ◽  
Nyall London ◽  
...  

Skull Base ◽  
2008 ◽  
Vol 18 (S 01) ◽  
Author(s):  
Annie Chan ◽  
Paul Busse ◽  
Urmila Kamat ◽  
Derrick Lin ◽  
Norbert Liebsch

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1862
Author(s):  
Eva Biewald ◽  
Tobias Kiefer ◽  
Dirk Geismar ◽  
Sabrina Schlüter ◽  
Anke Manthey ◽  
...  

Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14–97) months, mean follow-up was 22 (2–46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1–8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.


Sign in / Sign up

Export Citation Format

Share Document